Recent News

• 12.04.2025 - Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
• 12.04.2025 - Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
• 11.04.2025 - Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
• 11.04.2025 - Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
• 10.29.2025 - Axogen, Inc. Reports Third Quarter 2025 Financial Results
• 10.29.2025 - Axogen, Inc. Reports Third Quarter 2025 Financial Results

Recent Filings

• 12.04.2025 - 8-K Current report
• 12.04.2025 - EX-99.1 EX-99.1
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.12.2025 - 144 Report of proposed sale of securities
• 11.10.2025 - 144 Report of proposed sale of securities
• 11.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.06.2025 - 144 Report of proposed sale of securities
• 11.05.2025 - 144 Report of proposed sale of securities
• 10.31.2025 - 4 Statement of changes in beneficial ownership of securities